Eszopiclo-ne CAS 138729-47-2

Product Description:

Product Name: Eszopiclo-ne CAS NO: 138729-47-2

Synonyms:

[(7S)-6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate;

Esopiclone;

Lunesta;

Chemical & Physical Properties:

Appearance: White or slightly yellowish powder

Assay :≥99.0%

Density: 1.54 g/cm3

Boiling Point: 580.7℃ at 760 mmHg

Melting Point: 202-204℃

Flash Point: 305℃

Refractive Index: 1.688

Vapor Pressure: 1.78E-13mmHg at 25℃

Safety Information:

Safety Statements: S26-S36

HS Code: 2933599090

Risk Statements: R20/21/22; R36/37/38; R62

Hazard Code: Xn

Eszopiclo-ne, marketed by Sunovion under the brand-name Lunesta, is a nonbenzodiazepine hypnotic which is slightly effective for insomnia. Eszopiclo-ne is the active dextrorotatory stereoisomer of zopiclo-ne, and belongs to the class of drugs known as cyclopyrrolones.

Eszopiclo-ne (Lunesta) along with other "Z-drugs" including zolpidem (Ambien), zaleplon (Sonata) are the most commonly prescribed sedative hypnotics in the United States. Eszopiclo-ne is not marketed in the European Union following a 2009 decision by the EMA denying it new active substance status, in which it ruled that eszopiclo-ne was too similar to zopiclo-ne to be considered a new patentable product.

Eszopiclo-ne is now available in a generic form in the United States as of May 2014. On May 15, 2014, the USFDA asked that the starting dose of Eszopiclo-ne (Lunesta) be lowered from 2 milligrams to 1 milligram after it was observed in a study that even 8 hours after taking the drug at night, some patients were not able to cope with their next-day activities like driving and other activities that require full alertness.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.